Tradjenta 5 mg is a once-daily pill used to lower blood sugar in adults with type 2 diabetes. Its active ingredient, linagliptin, belongs to a class of medications called DPP-4 inhibitors. It’s prescribed alongside diet and exercise, either on its own or combined with other diabetes medications, to help keep blood sugar levels in a healthier range.
Tradjenta is not effective for type 1 diabetes or diabetic ketoacidosis, because those conditions involve a fundamentally different problem with insulin production that this drug can’t address.
How Tradjenta Lowers Blood Sugar
Your body naturally produces hormones called incretins after you eat. These hormones signal your pancreas to release insulin and tell your liver to stop pumping out excess sugar. The problem is that an enzyme called DPP-4 breaks down these hormones within minutes, cutting their action short.
Tradjenta blocks that enzyme. By preventing the breakdown of incretin hormones, it keeps them active longer, which means more insulin gets released when your blood sugar rises after a meal. Importantly, this process is glucose-dependent: the drug mainly boosts insulin when blood sugar is elevated, not when it’s already normal. That’s one reason the risk of dangerously low blood sugar is relatively low when Tradjenta is used on its own.
Where Tradjenta Fits in Diabetes Treatment
Tradjenta is typically considered when diet, exercise, and a first-line medication like metformin aren’t enough to reach blood sugar targets. It can be used alone if metformin isn’t tolerable, or added on top of other diabetes drugs including insulin.
Its role in treatment guidelines has shifted recently. The American College of Physicians removed DPP-4 inhibitors from their recommended add-on options in 2024, citing high-certainty evidence that these drugs don’t reduce the risk of death, heart attack, stroke, or heart failure hospitalization compared to usual care. They also noted DPP-4 inhibitors tend to be more expensive and less effective than alternatives like GLP-1 receptor agonists or SGLT2 inhibitors, which have demonstrated clear heart and kidney benefits. Other organizations, including the American Diabetes Association, still list DPP-4 inhibitors as an acceptable alternative, so prescribing practices vary.
A Notable Advantage for Kidney and Liver Disease
One feature that sets Tradjenta apart from other DPP-4 inhibitors is its dosing flexibility. Most diabetes medications need to be reduced or stopped as kidney function declines. Tradjenta does not require any dose adjustment at any level of kidney impairment, including in people on dialysis. This is because the drug is primarily eliminated through the digestive tract rather than filtered by the kidneys.
The same applies to liver disease. No dose adjustment is needed for mild or moderate liver impairment, and Tradjenta is the only DPP-4 inhibitor licensed for use in severe liver impairment. For people managing diabetes alongside significant kidney or liver problems, this can make it a practical choice when other options are limited.
Effects on Weight
Tradjenta is considered weight-neutral, meaning it doesn’t cause weight gain or weight loss on its own. This distinguishes it from some older diabetes medications like sulfonylureas or insulin, which commonly lead to weight gain. However, if you take Tradjenta alongside one of those medications, the combination may still result in some weight increase.
Common Side Effects
In clinical trials involving over 3,600 patients, the most frequently reported side effects were mild and included:
- Upper respiratory symptoms (nasopharyngitis), occurring in about 7% of patients
- Diarrhea, in about 3.3%
- Cough, in about 2.1%
These rates were only slightly higher than what was seen in people taking a placebo, suggesting the drug is generally well tolerated. Some people also reported muscle pain or allergic reactions such as hives or skin irritation.
Low Blood Sugar Risk
When used alone, Tradjenta carries a low risk of hypoglycemia. But when combined with sulfonylureas or insulin, the risk increases meaningfully. In clinical trials, about 6.6% of people on Tradjenta reported low blood sugar episodes, compared to 3.6% on placebo. Most of those cases occurred in people also taking another glucose-lowering drug. If you’re combining medications, your prescriber may lower the dose of the other drug to reduce this risk.
Pancreatitis
Inflammation of the pancreas (pancreatitis) is a rare but serious concern. In clinical trials, pancreatitis occurred at a rate of about 15 cases per 10,000 patient-years of Tradjenta use, compared to roughly 4 cases per 10,000 patient-years with placebo or other comparators. Symptoms to watch for include severe, persistent abdominal pain that may radiate to your back, often accompanied by nausea or vomiting.
Heart Health Considerations
Heart failure has been reported with some other DPP-4 inhibitors, but it has not been specifically linked to Tradjenta in clinical studies. That said, the broader class of DPP-4 inhibitors has not demonstrated the cardiovascular or kidney-protective benefits seen with newer drug classes like SGLT2 inhibitors and GLP-1 receptor agonists. If you have existing heart disease or are at high cardiovascular risk, those alternatives may offer more meaningful protection beyond blood sugar control alone.
Drug Interactions
Tradjenta has a relatively clean interaction profile. It is only a weak substrate of the liver enzyme CYP3A4, meaning drugs that affect that enzyme generally don’t cause major problems. Unlike most other DPP-4 inhibitors, which are cleared through the kidneys, Tradjenta is eliminated mostly through the gut as an unchanged drug. Strong enzyme inducers like rifampin (used to treat tuberculosis) can reduce Tradjenta’s effectiveness, so that combination is worth flagging with your prescriber if it applies to you.